A Randomized, Double-Blind, Placebo-Controlled Phase 1b Study Followed by an Open-Label Extension to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Topical AT193 in the Treatment of Patients With Nail Psoriasis
Latest Information Update: 02 Feb 2023
At a glance
- Drugs AT 193 (Primary)
- Indications Plaque psoriasis; Psoriatic arthritis
- Focus Adverse reactions
- Sponsors Azora Therapeutics
Most Recent Events
- 23 Jan 2023 Planned End Date changed from 1 Dec 2022 to 1 Aug 2023.
- 23 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Aug 2023.
- 23 Jan 2023 Status changed from recruiting to active, no longer recruiting.